Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of Dengue Vaccine in Healthy Children

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria :~* Aged 4 to 11 years on the day of inclusion.~* Participant in good health, based on medical history and physical examination.~* Provision of assent form signed by the participants (for participants \>= 7 years old) and informed consent form signed by the parent or another legally acceptable representative.~* Participant and parent/ legally acceptable representative able to attend all scheduled visits and to comply with all trial procedures.~* Participant attended one of the schools involved in the trial and living in the Ratchaburi Province.~* For a female participant of child-bearing potential (girls post-menarche), avoid becoming pregnant (use of an effective method of contraception or abstinence) for at least 4 weeks prior to first vaccination, until at least 4 weeks after the last vaccination.~Exclusion Criteria :~* Febrile illness (temperature \>= 37.5°C) or moderate or severe acute illness/infection on the day of vaccination, according to Investigator judgment.~* For a female participant of child-bearing potential (girls post-menarche), known pregnancy or positive urine pregnancy test on the day of the first trial vaccination.~* Personal or family history of thymic pathology (thymoma), thymectomy, or myasthenia.~* Planned participation in another clinical trial during the present trial period.~* Known or suspected congenital or acquired immunodeficiency, immunosuppressive therapy such as anti-cancer chemotherapy or radiation therapy, or long-term systemic corticosteroids therapy.~* Known systemic hypersensitivity to any of the vaccine components or history of a life-threatening reaction to the trial vaccines or to a vaccine containing any of the same substances.~* Chronic illness at a stage that could interfere with trial conduct or completion, in the opinion of the Investigator.~* Receipt of blood or blood-derived products in the past 3 months.~* Participant deprived of freedom by an administrative or court order, or in an emergency setting, or hospitalized without his/her consent.~* Participation in another clinical trial investigating a vaccine, drug, medical device, or a medical procedure in the 4 weeks preceding the first trial vaccination.~* Receipt of any vaccine in the 4 weeks preceding the first trial vaccination.~* Planned receipt of any vaccine in the 4 weeks following the first trial vaccination.e~* Participant who plans to attend another school (outside the trial area) or move to another city in the coming 30 months.

- Gender: ALL
- Minimum Age: 4 Years
- Maximum Age: 11 Years
- Healthy Volunteers: t

Study Arms:
- CYD Dengue Vaccine Group (Type: EXPERIMENTAL): Participants (both Cohort 1 and 2) received 3 injections of the CYD Dengue vaccine, 1 injection each at 0, 6, and 12 months.
- Control Group (Type: PLACEBO_COMPARATOR): Participants (Cohort 1) received rabies vaccine at Month 0 and placebo at 6 and 12 months. Participants (Cohort 2) received placebo at 0, 6, and 12 months.

Based on this trial design, predict the completion outcome and termination type (if applicable).